101603Advancing utrophin modulator SMTC1100 into clinical proof of concept trials for DMDClosedCollaborative R&DInnovate UKDuchenne Muscular Dystrophy (‘DMD’) is a fatal genetic disease that affects approximately 1,500 boys and young men in the UK. There is currently no disease modifying treatment for this progressive muscle wasting disease. Summit, a UK drug discovery and development company, is developing SMTC1100, a utrophin modulator drug that has the potential to treat all genetic forms of this disease. It has demonstrated significant potential in disease models of DMD and completed a Phase 1 clinical trial in healthy volunteers in 2012. The support of the TSB will allow this promising therapy to progress into patient clinical trials that aim to establish clinical proof of concept for SMTC1100 and validate it as a viable therapy for this devastating disease.